Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases
暂无分享,去创建一个
[1] Jutta Haider,et al. Understanding Knowledge as a Commons: From Theory to Practice , 2008, J. Documentation.
[2] A. Oduola,et al. The Malaria Research and Reference Reagent Resource (MR4) Center--creating African opportunities. , 2001, African journal of medicine and medical sciences.
[3] Christopher P. Austin,et al. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. , 2012, Cancer research.
[4] Min-Seok Kwon,et al. IDMap: facilitating the detection of potential leads with therapeutic targets , 2008, Bioinform..
[5] Malorye Allison,et al. NCATS launches drug repurposing program , 2012, Nature Biotechnology.
[6] C. Vilchèze,et al. Anthelmintic Avermectins Kill Mycobacterium tuberculosis, Including Multidrug-Resistant Clinical Strains , 2012, Antimicrobial Agents and Chemotherapy.
[7] Ruili Huang,et al. The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.
[8] Developing a framework for understanding and enabling open source drug discovery , 2010, Expert opinion on drug discovery.
[9] Enrique Seoane-Vazquez,et al. Incentives for orphan drug research and development in the United States , 2008, Orphanet journal of rare diseases.
[10] J. Peabody,et al. The Economics of Orphan Drug Policy in the US , 1995, PharmacoEconomics.
[11] Jyoti Yadav,et al. Open Source Drug Discovery , 2008 .
[12] M. Allarakhia,et al. Understanding and creating value from open source drug discovery for neglected tropical diseases , 2012, Expert opinion on drug discovery.
[13] B. Padhy,et al. Drug repositioning: re-investigating existing drugs for new therapeutic indications. , 2011, Journal of postgraduate medicine.
[14] Philip E. Bourne,et al. PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..
[15] Betty Y. S. Kim,et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.
[16] Luonan Chen,et al. Network-based drug repositioning. , 2013, Molecular bioSystems.
[17] 湯京平,et al. Understanding Knowledge as a Commons: From Theory to Practice , 2010 .
[18] L. Coles,et al. The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases , 2012, Clinical pharmacology and therapeutics.
[19] Jun O. Liu,et al. A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.
[20] E. Tambuyzer,et al. Rare diseases, orphan drugs and their regulation: questions and misconceptions , 2010, Nature Reviews Drug Discovery.
[21] Alexander E. Ivliev,et al. Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.
[22] Kate Marusina,et al. The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning. , 2011, Drug discovery today. Therapeutic strategies.
[23] Sherry L. Jenkins,et al. Network analysis of FDA approved drugs and their targets. , 2007, The Mount Sinai journal of medicine, New York.
[24] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[25] S. Walsh,et al. Managing knowledge assets under conditions of radical change: The case of the pharmaceutical industry , 2011 .
[26] Xiaomin Luo,et al. PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.
[27] Amanda L. Garner,et al. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis , 2010, Proceedings of the National Academy of Sciences.
[28] R. Campbell,et al. Target repurposing for neglected diseases. , 2011, Future medicinal chemistry.
[29] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[30] Philip E. Bourne,et al. Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..
[31] R. Mortara,et al. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. , 2007, The Journal of antimicrobial chemotherapy.
[32] Cheng Zhu,et al. Drug repositioning for orphan diseases , 2011, Briefings Bioinform..
[33] Youwen Zhou,et al. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? , 2010, Health policy.
[34] E. Ostrom,et al. A Framework for Analyzing the Knowledge Commons : a chapter from Understanding Knowledge as a Commons: from Theory to Practice. , 2005 .
[35] Laurent Ségalat,et al. High‐throughput screening and small animal models, where are we? , 2010, British journal of pharmacology.
[36] A. Renslo,et al. Drug discovery for neglected tropical diseases at the Sandler Center. , 2011, Future medicinal chemistry.
[37] Robert B. Russell,et al. SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..
[38] B. Lundvall. National Systems of Innovation , 1992 .
[39] Kui Xu,et al. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases , 2011, Briefings Bioinform..
[40] E. Chatelain,et al. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? , 2012, International journal for parasitology. Drugs and drug resistance.
[41] Sean Ekins,et al. In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.
[42] Ramaiah Muthyala,et al. Orphan/rare drug discovery through drug repositioning , 2011 .
[43] Tudor I. Oprea,et al. Drug Repurposing from an Academic Perspective. , 2011, Drug discovery today. Therapeutic strategies.
[44] K. Green. National innovation systems: a comparative analysis , 1996 .
[45] S. Sundar,et al. Oral miltefosine for the treatment of Indian visceral leishmaniasis. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[46] Jaijit Bhattacharya,et al. Open source drug discovery--a new paradigm of collaborative research in tuberculosis drug development. , 2011, Tuberculosis.